Field Medical Reports 12-Month Field PULSE Trial Results

Atlanta and Carlsbad, California, September 20, 2026

Field Medical Advances High-Voltage Focal PFA

The FieldForce PFA System was developed around a high-voltage focal PFA architecture designed to provide precise energy delivery during cardiac ablation. Field Medical is evaluating the technology in both ventricular and atrial applications, with the Field PULSE study extending the platform into the atrium for treatment of atrial fibrillation. The company describes its workflow as “instantaneous ablation,” based on energy delivery in less than 200 milliseconds, potentially reducing the need for prolonged catheter stability while retaining the flexibility of point-by-point ablation. The Field PULSE trial evaluated whether this focal PFA approach could provide efficient pulmonary vein isolation while maintaining durable lesions.

Pulmonary vein isolation is an important component of many AF ablation procedures because electrical signals originating around the pulmonary veins can contribute to recurrent atrial arrhythmias. Field Medical reported a 13-minute median elapsed PVI ablation time, with the fastest procedure completed in 7.7 minutes. The study also demonstrated that the platform could be used beyond pulmonary vein targets. According to the company, 49% of patients received non-PV ablation for additional atrial targets, highlighting the flexibility of a focal point-by-point approach for individualized ablation strategies.

Optimized Waveform Shows Durable PVI Outcomes

One of the key findings from the 12-month analysis was the reported 94.2% per-vein PVI durability with the optimized waveform. Field Medical said the results reflected progressive improvement in durability as the waveform evolved during clinical development. The company also reported 80% freedom from atrial arrhythmias at 12 months among patients treated with the optimized waveform. The study reported no primary safety events, adding to the safety observations from the first-in-human evaluation. However, the results come from an early-stage clinical study, and the FieldForce system remains investigational. The reported findings therefore represent clinical evidence generated during device development rather than evidence of an established or approved treatment. The publication in JACC: Clinical Electrophysiology adds peer-reviewed evidence to Field Medical’s PFA development program. The study, titled “High-Voltage Focal PFA Catheter for ‘Instant’ Point-By-Point Ablation: The First-In-Human FIELD-PULSE Trial to Treat AF,” was published online alongside the HRX presentation.

FieldForce Platform Expands Cardiac Ablation Research

Field Medical said the Field PULSE results build on its earlier clinical work in ventricular tachycardia (VT). The company’s first-in-human VCAS trial evaluated its high-voltage focal PFA architecture in ventricular applications, with six-month findings previously published in Circulation. Field PULSE now adds first-in-human atrial data and demonstrates the company’s efforts to apply the platform across different cardiac substrates. The company received FDA Breakthrough Device Designation in 2024 and entered the FDA TAP Pilot Program for its ventricular tachycardia indication. These regulatory milestones form part of Field Medical’s broader development strategy for focal PFA technology, although the FieldForce PFA System remains limited to investigational use under U.S. federal law.

For the broader MedTech and electrophysiology sectors, the Field PULSE findings highlight continued development of PFA systems designed to combine rapid energy delivery with focal treatment flexibility. The reported 12-month PVI durability, arrhythmia-free outcomes and procedural efficiency provide additional clinical data for Field Medical as it continues development of its investigational technology. Further clinical evaluation will be important to establish the safety, effectiveness and potential applications of the FieldForce platform in larger patient populations.

Source: Field Medical press release